TABLE 1.
Baseline characteristics
| Characteristics | All patients (N=1038) | Group 1 (2001–2005; N=477) | Group 2 (2006–2010; N=561) |
|---|---|---|---|
| Age (years)* | 66 (50, 79) | 65 (50, 80) | 66 (50, 78) |
| Age > 65 | 52% | 50% | 54% |
| Age > 75 | 19% | 22% | 17% |
| Gender: Male | 59% | 60% | 58% |
| ISS Stage 1 | 30% | 35% | 26% |
| ISS Stage 2 | 39% | 36% | 42% |
| ISS Stage 3 | 31% | 29% | 32% |
| Serum creatinine (mg/dl)* | 1.1 (0.8, 2.3) | 1.2 (0.9, 2.5) | 1.0 (0.7, 2) |
| Serum creatinine > 2.0 mg/dL | 12% | 14% | 10% |
| Serum B2M (mg/dL)* | 3.9 (2, 11.4) | 3.8 (2, 11.7) | 3.9 (2.2, 10.7) |
| Serum LDH (IU/dL)* | 158 (110, 269) | 155 (107, 265) | 161 (112, 272) |
| Serum Calcium (mg/dL)* | 9.5 (8.5, 10.5) | 9.5 (8.4, 10.5) | 9.6 (8.6, 10.6) |
| Hemoglobin (g/dL)* | 10.8 (8.6, 13.6) | 10.7 (8.6, 13.3) | 10.9 (8.6, 13.8) |
| BMPC% | 50 (18, 80) | 50 (18, 80) | 50 (15, 84) |
| IgG (g/dL)* | 2.0 (0.3, 6.7) | 2.0 (0.3, 6.2) | 2.0 (0.3, 6.8) |
| IgA (mg/dL)* | 51 (11, 3200) | 51 (12, 3400) | 52 (10, 2900) |
| Kappa: Lambda | 66:34 | 65:35 | 67:33 |
| Light chain MM | 17% | 17% | 17% |
| High Risk MM# | 12% | 12% | 12% |
*
Represent median (10th percentile, 90th percentile)
#
defined as presence of (t(4;14), t(14;16), t(16;20), or del 17p in the absence of any trisomy